APA (7th ed.) Citation

Margetić, S., Ćelap, I., Brkljačić, D. D., Pavlović, N., Goreta, S. Š., Kobasić, I., . . . Kes, V. B. (2020). Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: Possibilities and limitations. Biochemia Medica, 30(1), 1. https://doi.org/10.11613/BM.2020.010702

Chicago Style (17th ed.) Citation

Margetić, Sandra, Ivana Ćelap, Diana Delić Brkljačić, Nikola Pavlović, Sandra Šupraha Goreta, Ivana Kobasić, Arijana Lovrenčić-Huzjan, and Vanja Bašić Kes. "Chromogenic Anti-FXa Assay Calibrated with Low Molecular Weight Heparin in Patients Treated with Rivaroxaban and Apixaban: Possibilities and Limitations." Biochemia Medica 30, no. 1 (2020): 1. https://doi.org/10.11613/BM.2020.010702.

MLA (9th ed.) Citation

Margetić, Sandra, et al. "Chromogenic Anti-FXa Assay Calibrated with Low Molecular Weight Heparin in Patients Treated with Rivaroxaban and Apixaban: Possibilities and Limitations." Biochemia Medica, vol. 30, no. 1, 2020, p. 1, https://doi.org/10.11613/BM.2020.010702.